British American Tobacco (Malaysia) Berhad (4162) Fair Value & Analysis
Consumer Defensive · MY · Market cap 1.4B MYR
Fair value as of: Jun 24, 2026
Analysis
British American Tobacco (Malaysia) Berhad (4162) currently trades at 5.14 MYR, while our model-based Fair Value estimate is 8.24 MYR — implying the stock looks roughly 60.3% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
British American Tobacco (Malaysia) Berhad engages in the manufacture, sale, marketing and importation of cigarettes, pipe tobaccos, cigars, devices, other tobacco products, and nicotine products in Malaysia. It sells tobacco products under the Dunhill, Peter Stuyvesant, Rothmans, Benson & Hedges, KYO, and Luckies brands; tobacco heating products under the glo brand; and nicotine vapor products under the Vuse brand. The company was founded in 1912 and is headquartered in Kuala Lumpur, Malaysia. It serves adult nicotine consumers, retailers, wholesalers, and business partners, and engages with government agencies, industry bodies, and local communities. British American Tobacco (Malaysia) Berhad operates as a subsidiary of British American Tobacco Holdings Malaysia B V.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is British American Tobacco (Malaysia) Berhad (4162) undervalued?
What is the fair value of 4162?
What is the quality score of 4162?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.